Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4H2B

Human ecto-5'-nucleotidase (CD73): crystal form II (open) in complex with Baicalin

Summary for 4H2B
Entry DOI10.2210/pdb4h2b/pdb
Related4H1Y 4h2f 4h2g 4h2i
Descriptor5'-nucleotidase, ZINC ION, 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronic acid, ... (6 entities in total)
Functional Keywordsdimer, hydrolase phosphatase nucleotidase, extracellular, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHomo sapiens (human)
Cellular locationCell membrane; Lipid-anchor, GPI-anchor: P21589
Total number of polymer chains1
Total formula weight61214.16
Authors
Zebisch, M.,Pippel, J.,Knapp, K.,Straeter, N. (deposition date: 2012-09-12, release date: 2012-11-28, Last modification date: 2024-11-06)
Primary citationKnapp, K.,Zebisch, M.,Pippel, J.,El-Tayeb, A.,Muller, C.E.,Strater, N.
Crystal Structure of the Human Ecto-5'-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling.
Structure, 20:2161-2173, 2012
Cited by
PubMed Abstract: In vertebrates ecto-5'-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels. Due to its pivotal role for activation of P1 adenosine receptors, e5NT has emerged as an appealing drug target for treatment of inflammation, chronic pain, hypoxia, and cancer. Crystal structures of the dimeric human e5NT reveal an extensive 114° conformational switch between the open and closed forms of the enzyme. The dimerization interface is formed by the C-terminal domains and exhibits interchain motions of up to 13°. Complex structures with adenosine and AMPCP indicate that structural control of the domain movement determines the selectivity for monophosphate nucleotides. Binding modes of nucleotide-derived and flavonoid-based compounds complexed to the C-terminal domain in the open form reveal an additional binding pocket of ∼210 Å(3) that might be explored to design more potent inhibitors.
PubMed: 23142347
DOI: 10.1016/j.str.2012.10.001
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.7 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon